Statins activate cell death-related mechanisms via PI3K/AKT and MAPK/ERK signaling, acting as an effect of the reversion of the metabolic products of the mevalonate pathway or the cholesterol synthesis pathway in breast cancer cells [63]. The gene discussed is MAPK1; the disease is breast carcinoma.